^a Tested in dextrose 5%.

^b Tested in sodium chloride 0.9%.

^c Tested in dextrose 5% in sodium chloride 0.9%.

^d Flowing at 1.6 mL/min.

^e Tested in dextrose 5% in Ringer’s injection, dextrose 5% in Ringer’s injection, lactated, dextrose 5%, Ringer’s injection, lactated, and sodium chloride 0.9%.

^f Tested with albumin human 0.1%.

^g Tested in sterile water for injection.

^h Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.

ⁱ Injected via Y-site into an administration set running azithromycin.

^j Tested in either dextrose 5% or in sodium chloride 0.9%, but the report did not specify which solution.

^k Tested in a 1:1 mixture of (1) dextrose 5% and dextrose 5% in sodium chloride 0.45% with and without potassium chloride 20 mEq/L and also in (2) dextrose 10% in sodium chloride 0.45% with and without potassium chloride 20 mEq/L.

^l Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.

^m Tested in Ringer’s injection, lactated.

ⁿ Tested undiluted.

^o Tested in both dextrose 5% and sodium chloride 0.9%.

^p Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.

^q Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.

^r Test performed using the formulation WITH edetate disodium.

^s Imipenem component. Imipenem in a 2:2:1 fixed-ratio concentration with cilastatin and relebactam.

^t Salt not specified.

^u Tested with rocuronium bromide (MPC) 10 mg/mL.

^v Tested with vecuronium bromide (MPC) 1 mg/mL.

^w Tested with remimazolam besylate (MUN) 5 mg/mL.